CJC-1295 / Ipamorelin Blend 10 mg

Product Description

Concentration

• 10 mg total per vial
  • 5 mg CJC-1295 (No DAC)
  • 5 mg Ipamorelin

Physical Form

• White lyophilized powder in a sterile 3 mL vial

Product Features

• Dual-peptide freeze-dried blend for convenient single-vial reconstitution
  
  
• Butyl rubber stopper allows multiple punctures while maintaining a secure seal
  
  
• RTF vials are depyrogenated and ETO-sterilized
  
  
• Tamper-evident aluminum flip-top protects product integrity

Research Highlights

• Synergistic GH Release: CJC-1295 (No DAC) stimulates GHRH receptors while Ipamorelin targets ghrelin receptors, yielding a stronger, physiologic growth-hormone pulse without overstimulating IGF-1.
  
  
• Muscle & Tissue Support: Elevated GH can enhance protein synthesis, aid muscle recovery, and promote collagen formation—benefits observed in models of injury, surgery, and glucocorticoid-induced catabolism.
  
  
• Bone Density & Joint Health: Ipamorelin studies indicate improved bone mineral density and reduced glucocorticoid-related bone loss; CJC-1295 may further augment anabolic signaling for skeletal support.
  
  
• Metabolic & Glycemic Insights: Data suggest improved nitrogen balance, increased fat oxidation, and potential modulation of insulin release—valuable endpoints for metabolic-health exploration.
  
  
• GI & Cardiac Applications: Ipamorelin shows promise in post-operative ileus studies, while CJC-1295 (and related GRF analogues) are being examined for cardiac remodeling and intestinal motility research.

Blend Rationale: Combining these two selective secretagogues provides complementary receptor activation, mimicking natural pituitary rhythms more closely than single-agent protocols.

Important Terms

For research use only (RUO). Not intended for human consumption or for use in medical, veterinary, or household applications. By purchasing this product, you agree to comply with all stated Terms & Conditions.